Clemens Christian Cyran1, Philipp Marius
Paprottka1, Bettina Schwarz2, Jobst von Einem1,
Steven Sourbron1, Olaf Dietrich1, Rabea Hinkel3,
Christiane J. Bruns2, Hubertus Pietsch4, Bernd J.
Wintersperger1, Maximilian F. Reiser1, Konstantin
Nikolaou1
1Institute of Clinical Radiology,
Munich University Hospitals - Campus Grosshadern, Munich, Germany; 2Department
of Surgery, Munich University Hospitals - Campus Grosshadern, Munich,
Germany; 3Department of Cardiology, Munich University Hospitals -
Campus Grosshadern, Munich, Germany; 4Contrast Media Research,
Bayer Schering Pharma AG, Berlin, Germany
The
purpose of this study was to investigate the effects of Sorafenib on
experimental prostate carcinomas in rats by dynamic MRI enhanced with
Gadobutrol. Target parameters were tumor perfusion and tumor endothelial
permeability. Tumor perfusion (ml/100ml/min), assayed by DCE-MRI enhanced
with the small molecular contrast medium Gadobutrol, decreased significantly
(p<0.01) in experimental prostate carcinomas treated with a daily,
one-week treatment course of Sorafenib (10mg/kg bodyweight). In the control
group, tumor perfusion increased significantly (p<0.05) over the
experimental course of 7 days. No significant change was observed regarding
the endothelial permeability in tumors, neither in the therapy nor in control
group.